MAVENIR
4.4.2022 09:02:11 CEST | Business Wire | Press release
Vodafone Portugal, a leading telecom provider in Portugal, and Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that Vodafone Portugal will be using the MAVcore solution for its fully containerised Converged Packet Core network after the selection of Mavenir as strategic 5G Converged Core supplier.
The MAVcore family includes Mavenir’s leading-edge Converged Packet Core and Policy Control solution delivering a next-generation modernised data network. The MAVcore solution will allow the transformation to a containerised and automated cloud-native network – providing the flexibility for future mobile network evolution, including the launch of disruptive and innovative 5G Stand Alone applications for Vodafone customers in Portugal.
The 5G Converged Packet Core solution is designed with cloud-native containerised techniques providing a fully scalable and virtualised network architecture. The solution uses software running on commercial off-the-shelf (COTS) hardware that provides cost-effectiveness, flexibility, and agility. Mavenir Converged Packet Core with multi-access support (2G, 3G, 4G, 5G) allows Communication Service Providers (CSPs) like Vodafone to plan for future growth and a greater focus on security and reliability. It simplifies network transformation and enables operational efficiencies with complete automation.
Paulino Correa, Network Director, Vodafone Portugal, said; “The industry defines several steps for 5G – the first one was launched back in November – but it is the second step, the 5G Stand Alone Core, that brings the more powerful technology revolution in terms of use cases. For our strategic 5G Stand Alone Core supplier, we wanted a vendor who would have innovation at its heart and equally provide us with a technically leading converged Packet Core solution. We have been working on 5G SA with Mavenir in our lab for over 1 year and are now ready to deliver a cloud-native Packet Core platform that will transform our network and prepare it for powerful applications and differentiating use cases, as the 5G solution evolves.”
Stefano Cantarelli, Chief Marketing Officer, Mavenir, said; “Mavenir has been working with Vodafone Group across various projects and we are delighted to now be part of their next-generation Converged Packet Core network under the Spring 3 Cosmos programme – we look forward to transforming Vodafone Portugal’s existing network into a dynamic, agile, fully automated for simplified operation and cloud-native based platform.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Vodafone Portugal:
Vodafone Portugal is part of the Vodafone Group which is a leading technology communications company. Vodafone is the largest mobile and fixed network operator in Europe and a leading global IoT connectivity provider. Vodafone Group operates mobile and fixed networks in 21 countries and partner with mobile networks in 48 more. Vodafone Portugal currently serves 3.6 million homes and businesses with its next generation network and has over 4.6 million mobile customers.
https://www.vodafone.pt/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom